Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Infinity Pharmaceuticals, Inc. clinical trials
The registry lists 21 studies whose lead sponsor is Infinity Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 14, 2023.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Infinity Pharmaceuticals, Inc..
- Infinity Pharmaceuticals, Inc.21 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 21 of 21.
- Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaActive, not recruitingNCT03961698Phase 2
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedNCT03980041Phase 2
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
- A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic CancerCompletedNCT01130142Phase 1/2
- Dose Escalation of IPI-493 in Hematologic MalignanciesTerminatedNCT01193491Phase 1
- A Phase 1 Dose Escalation Study of IPI-493TerminatedNCT00724425Phase 1
- Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnNCT00969917Phase 2
- Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung CancerCompletedNCT01427946Phase 1/2
- A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerCompletedNCT01362400Phase 2
- A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) ChondrosarcomaCompletedNCT01310816Phase 2
- Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerTerminatedNCT00817362Phase 2
- Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
- A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate CancerCompletedNCT00564928Phase 2
- A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic MelanomaTerminatedNCT00627419Phase 2
- Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT00431015Phase 1/2
- A Phase 2 Study With IPI-926 in Patients With MyelofibrosisCompletedNCT01371617Phase 2
- IPI-926 Extension Protocol for Continuation of Treatment With IPI-926CompletedNCT01609179Not applicable
- A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor MalignanciesCompletedNCT00761696Phase 1
- Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid TumorsCompletedNCT00606814Phase 1
- Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)CompletedNCT00276302Phase 1
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple MyelomaCompletedNCT00113204Phase 1